


글로벌 제약사 파이프라인 분석

- Bayer -

2022. 08.


국가신약개발사업단

• 질환별 파이프라인



질환분야	개수	비중
Cardiovascular	14	34%
Oncology	13	32%
Neuroscience	3	7.3%
Others	3	7.3%
Ophthalmology	3	7.3%
Metabolic	2	4.9%
Renal	1	2.4%
Respiratory	1	2.4%
Immunology	1	2.4%
합계	41개	100%

• 물질별 파이프라인



물질	개수	비중
Small molecules	20	48.8%
N/A (Not applicable)	10	24.4%
Gene therapy	4	9.8%
Protein	2	4.9%
Antibody	2	4.9%
RNA	1	2.4%
Cell therapy	1	2.4%
Peptide	1	2.4%
합계	41개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Cardiovascular	Phase 3	BAY 94-8862		finerenone	Heart failure	Small molecules	Mineralocorticoid receptor	Mineralocorticoid receptor antagonist	Mono	-
2	Cardiovascular	Phase 3	BAY 94-8862		finerenone	Non-diabetic CKD	Small molecules	Mineralocorticoid receptor	Mineralocorticoid receptor antagonist	Mono	-
3	Cardiovascular	Phase 3	BAY-1021189		vericiguat	Heart failure	Small molecules	sGC	sGC activator	Mono	-
4	Cardiovascular	Phase 2	BAY-1213790		osocimab	Thrombosis prevention in ESRD	Antibody	Factor XI α	Factor XI α inhibitor	Mono	-
5	Cardiovascular	Phase 2	BAY-2306001		fesomersen	Thrombosis prevention in ESRD	RNA	Factor XI	Factor XI inhibitor	Mono	Ionis
6	Cardiovascular	Phase 2	BAY-2433334		asundexian	Stroke prevention in atrial fibrillation	Small molecules	Factor XI α	Factor XI α inhibitor	Mono	-
7	Cardiovascular	Phase 2	BAY-2433334		asundexian	Secondary prevention of stroke	Small molecules	Factor XI α	Factor XI α inhibitor	Mono	-
8	Cardiovascular	Phase 2	BAY-2433334		asundexian	Major adverse cardiac events prevention	Small molecules	Factor XI α	Factor XI α inhibitor	Mono	-
9	Cardiovascular	Phase 1			N/A	Congestive heart failure	Gene therapy	N/A	N/A	Mono	-
10	Cardiovascular	Phase 1			mosliciguat	Cardiovascular diseases	Small molecules	sGC	sGC activator	Mono	-
11	Cardiovascular	Phase 1			enuvaptan	Cardiovascular diseases	Small molecules	Vasopressin V1a receptor	Vasopressin V1a receptor antagonist	Mono	-
12	Cardiovascular	Phase 1			N/A	Cardiovascular diseases	Small molecules	sGC	sGC activator 4	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
13	Cardiovascular	Phase 1			N/A	Endometriosis	N/A	P2X4	P2X4 antagonist	Mono	-
14	Cardiovascular	Phase 1			N/A	Endometriosis	N/A	BDKRB1	BDKRB1 receptor antagonist	Mono	-
15	Immunology	Phase 1	BAY-1834845		zabedoseritib	Psoriasis	N/A	IRAK4	IRAK4 inhibitor	Mono	-
16	Metabolic	Phase 3	NT-814		elinzanetanant	Vasomotor symptoms	Small molecules	NK1R, NK3R	NK1R, NK3R antagonist	Mono	-
17	Metabolic	Phase 1			N/A	Pompe disease	Gene therapy	N/A	N/A	Mono	-
18	Neuroscience	Phase 2			N/A	Neuropathin pain	N/A	N/A	BDKRB1 receptor antagonist	Mono	-
19	Neuroscience	Phase 1			N/A	Parkinson's disease	Gene therapy	N/A	N/A	Mono	-
20	Neuroscience	Phase 1			N/A	Parkinson's disease	Cell therapy	N/A	N/A	Mono	-
21	Oncology	Phase 3	BAY 73-4506	Stivarga	regorafenib	Glioblastoma	Small molecules	Tie2, VEGFR-2	Multi-Kinase inhibitor	Mono	-
22	Oncology	Phase 3	BAY 80-6946	Aliqopa	copanlisib	Non-Hodgkin lymphoma	Small molecules	PI3K	PI3K inhibitor	Mono	-
23	Oncology	Phase 3	BAY-1841788	Nubeqa	darolutamide	Metastatic hormone-sensitive prostate cancer	Small molecules	AR	AR inhibitor	Mono	Orion Corp
24	Oncology	Phase 3	BAY-1841788	Nubeqa	darolutamide	Adjuvant prostate cancer	Small molecules	AR	AR inhibitor	Mono	Orion Corp
25	Oncology	Phase 2	BAY 73-4506	Stivarga	regorafenib	Recurrent/metastatic solid tumors	Small molecules	Tie2, VEGFR-2	Multi-Kinase inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
26	Oncology	Phase 2	BAY 73-4506	Stivarga	regorafenib	Hepatocellular carcinoma	Small molecules	Tie2, VEGFR-2	multi-Kinase inhibitor	Mono	-
27	Oncology	Phase 1			elimusertib	Cancer	Small molecules	ATR	ATR inhibitor	Mono	-
28	Oncology	Phase 1			N/A	Cancer	N/A	N/A	SLFN12 Complex-inducer	Mono	Calico Life Sciences
29	Oncology	Phase 1			N/A	Cancer	N/A	N/A	mEGFR inhibitor	Mono	Alector
30	Oncology	Phase 1			N/A	Cancer	N/A	N/A	PSMA-targeted thorium conjugate	Mono	Roche
31	Oncology	Phase 1			N/A	Cancer	N/A	N/A	HER2-targeted thorium conjugate	Mono	Roche
32	Oncology	Phase 1			bapotulimab	Cancer	Antibody	ILDR2	ILDR2 antibody	Mono	-
33	Oncology	Phase 1			N/A	Cancer	N/A	AhR	AhR inhibitor	Mono	-
34	Ophthalmology	Phase 3		Eylea	aflibercept	Diabetic macular edema	Protein	VEGF-A	VEGF-A inhibitor	Mono	Genmab
35	Ophthalmology	Phase 3		Eylea	aflibercept	Neovascular age-related macular degeneration	Protein	VEGF-A	VEGF-A inhibitor	Mono	-
36	Ophthalmology	Phase 2			runcaciguat	Non-proliferative diabetic retinopathy	Small molecules	sGC	sGC activator	Mono	-
37	Others	Phase 1			N/A	Hemophilia A	Gene therapy	N/A	N/A	Mono	-
38	Others	Phase 1			N/A		Small molecules	sGC	sGC activator 3	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
39	Others	Phase 1			N/A		N/A	ADRA2C	ADRA2C antagonist	Mono	-
40	Renal	Phase 2			runcaciguat	Chronic kidney disease	Small molecues	sGC	sGC activator	Mono	-
41	Respiratory	Phase 2	BAY-1097761		adrenomedullin pegol	Acute respiratory distress syndrome	Peptide	N/A	N/A	Mono	-

자료: Bayer 홈페이지, BioCentury, GlobalData